FBIO shares have settled below the $2 threshold, trading near $1.80 after a stretch of elevated intraday volatility around the company's November 13, 2026 third-quarter earnings release. The stock ended the preceding session at $1.89 and slipped roughly 7% over the trailing 30 days from a closing level of $1.94 in late October. The broader picture is steeper: from above $2.80 in mid-August, the shares have declined about 36% over the quarter, a move that contrasts with steady commercial progress and a strengthened balance sheet. Sentiment across micro- and small-cap biopharma has remained selective, and FBIO's sub-$2 pricing keeps the shares in a range where small dollar moves translate into large percentage swings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Fortress Biotech, Inc. operates an asset-acquisition model focused on acquiring and advancing pharmaceutical products and development programs across a network of majority-owned, majority-controlled, and minority-owned subsidiaries and partner companies. The company generates value through product revenue, equity holdings, and dividend and royalty income, spanning therapeutic areas that include oncology, dermatology, and rare diseases. Its best-known commercial engine is Journey Medical Corporation (DERM), which markets branded dermatology products and has driven the recent growth of Emrosi, a minocycline-based rosacea therapy. The wider portfolio includes royalty interests tied to Unloxcyt, Zycubo, and other partnered assets, alongside partnerships with institutions such as AstraZeneca, City of Hope, and Cedars-Sinai. This diversified structure spreads risk across multiple programs, though it also means shareholder value is influenced by the performance of several independently managed entities.
Fortress reported third-quarter 2026 results on November 13, 2026, posting consolidated net revenue of $19.2 million, up about 9% from $17.6 million a year earlier. Net product revenue of $18.9 million was driven by Journey Medical, where Emrosi reached approximately 40,000 total prescriptions in the quarter and surpassed 5,000 unique prescribers. The company reported a consolidated net loss attributable to common stockholders of $7.9 million, or $0.23 per share, compared with net income of $3.7 million in the prior-year period. Financially, Fortress repaid the remaining $15 million under its Oaktree credit facility in September 2026, removing parent-level debt, and held $152.2 million in cash and equivalents at quarter-end. On the pipeline side, anselamimab was approved in Japan in September 2026 for systemic kappa light chain amyloidosis, a subsidiary licensed FB-607 from Cedars-Sinai for IBS-D, and Crystalys Therapeutics closed a $130 million Series B to advance dotinurad for gout. These developments improved the fundamental backdrop even as the share price continued to slide. From what I see, reviewing the pipeline updates through Tickeron’s AI Trend Prediction Engine helped confirm the timing of these catalysts.
Looking ahead, the most important near-term driver is the expected addition of Emrosi to a national health plan formulary covering roughly 25 million lives beginning in January 2027, which management has cited as a potential catalyst for a higher proportion of reimbursed prescriptions and improving average selling prices. Investors will also monitor prescription growth, refill rates, and prescriber expansion at Journey Medical, along with consolidated progress toward sustained profitability. On the development front, top-line Phase 2 data for FB-607 in IBS-D is not expected until the second half of 2027, while partner programs such as dotinurad and royalty streams tied to Unloxcyt and Zycubo remain longer-term value drivers. Key risks include clinical and regulatory uncertainty across subsidiary programs, the modest scale of current revenue relative to operating expenses, and the volatility that often accompanies sub-$2 biopharmaceutical equities. I’m watching this closely as the formulary decision approaches.
In my analysis, I often turn to Tickeron’s Trending AI Robots to supplement fundamental views with systematic signals. This platform offers a range of data-driven strategies that help identify potential opportunities across various timeframes and risk levels. It’s a practical way to add another layer to traditional research when evaluating names like FBIO.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
FBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 35 cases where FBIO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FBIO's RSI Indicator exited the oversold zone, 32 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 69 cases where FBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for FBIO just turned positive on October 20, 2026. Looking at past instances where FBIO's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Following a +10.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where FBIO advanced for three days, in 204 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FBIO as a result. In 70 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for FBIO entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.376) is normal, around the industry mean (3.592). P/E Ratio (0.569) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1.145) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. FBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of novel immunotherapy biologic agents
Industry Biotechnology